{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:39:54Z","timestamp":1789767594319,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.106023","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:23:38Z","timestamp":1767036218000},"page":"106023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4470-1783","authenticated-orcid":false,"given":"S.-C.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-S.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-2413","authenticated-orcid":false,"given":"C.-C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-5067","authenticated-orcid":false,"given":"J.-Y.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-689X","authenticated-orcid":false,"given":"S.-G.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-6324","authenticated-orcid":false,"given":"P.-W.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-0733","authenticated-orcid":false,"given":"C.-L.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7255","authenticated-orcid":false,"given":"C.-Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-3470","authenticated-orcid":false,"given":"W.-Y.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.106023_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.esmoop.2025.106023_bib2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106023_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40291-024-00736-8","article-title":"Profiling cell-free DNA from malignant pleural effusion for oncogenic driver mutations in patients with treatment-naive stage IV adenocarcinoma: a multicenter prospective study","volume":"28","author":"Chang","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.esmoop.2025.106023_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100399","article-title":"Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer","volume":"7","author":"Heitzer","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.106023_bib5","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.esmoop.2025.106023_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.21037\/tlcr-20-882","article-title":"A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer","volume":"9","author":"Jin","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106023_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.106023_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2023.02.023","article-title":"Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer","volume":"178","author":"Daher","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2025.106023_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.613071","article-title":"Cell-free DNA from pleural effusion samples: is it right for molecular testing in lung adenocarcinoma?","volume":"27","author":"Mok\u00e1nszki","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.esmoop.2025.106023_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.106023_bib11","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.18632\/oncotarget.7189","article-title":"The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2025.106023_bib12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106023_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.106023_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2025.106023_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2025.106023_bib16","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jtho.2016.12.024","article-title":"Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC","volume":"12","author":"Chen","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.106023_bib17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","article-title":"Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor","volume":"10","author":"Kim","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.106023_bib18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106023_bib19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.106023_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.12.039","article-title":"The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance","volume":"153","author":"Fuchs","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2025.106023_bib21","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/biomedicines12071412","article-title":"Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms \u2013 an in vitro study","volume":"12","author":"Fukuda","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.esmoop.2025.106023_bib22","article-title":"MYC and non-small cell lung cancer: a comprehensive review","volume":"37","author":"Kenzerki","year":"2023","journal-title":"Human Gene"},{"key":"10.1016\/j.esmoop.2025.106023_bib23","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.21037\/tlcr-22-176","article-title":"MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report","volume":"11","author":"Choi","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106023_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pccm.2023.07.001","article-title":"Role of C-Myc in lung cancer: progress, challenges, and prospects","volume":"1","author":"Wallbillich","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"10.1016\/j.esmoop.2025.106023_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:35:46Z","timestamp":1768811746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925018939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925018939"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106023","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106023"}}